{"id":1112,"date":"2001-01-01T12:04:00","date_gmt":"2001-01-01T11:04:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/2-chlordesoxyadenosin-plus-prednison-versus-chlorambucil-plus-prednison-als-primaere-therapie-bei-chronischer-lymphatischer-leukaemie"},"modified":"2022-03-17T14:09:54","modified_gmt":"2022-03-17T13:09:54","slug":"2-chlordesoxyadenosin-plus-prednison-versus-chlorambucil-plus-prednison-als-primaere-therapie-bei-chronischer-lymphatischer-leukaemie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2001\/2-chlordesoxyadenosin-plus-prednison-versus-chlorambucil-plus-prednison-als-primaere-therapie-bei-chronischer-lymphatischer-leukaemie","title":{"rendered":"2-Chlordesoxyadenosin plus Prednison versus Chlorambucil plus Prednison als prim\u00e4re Therapie bei chronischer lymphatischer Leuk\u00e4mie"},"content":{"rendered":"<p>Wir haben in den vergangenen Jahren wiederholt \u00fcber randomisierte klinische Studien zur Behandlung der chronischen lymphatischen Leuk\u00e4mie (CLL) berichtet, in denen &#8211; abh\u00e4ngig vom Stadium der Erkrankung &#8211; Chlorambucil (CBL) plus Kortikosteroide (z.B. Prednison) mit abwartendem Verhalten bzw. intensiver Kombinationschemotherapie verglichen wurden (s. AMB 1990, 24, 69; 1992, 26, 5; 1998, 32, 53b). Diese Studien [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wir haben in den vergangenen Jahren wiederholt \u00fcber randomisierte klinische Studien zur Behandlung der chronischen lymphatischen Leuk\u00e4mie (CLL) berichtet, in denen &#8211; abh\u00e4ngig vom Stadium der Erkrankung &#8211; Chlorambucil (CBL) plus Kortikosteroide (z.B. Prednison) mit abwartendem Verhalten bzw. intensiver Kombinationschemotherapie verglichen wurden (s. AMB 1990, 24, 69; 1992, 26, 5; 1998, 32, 53b). Diese Studien [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[189,705,799,188],"class_list":["post-1112","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-2-chlordesoxyadenosin","tag-chlorambucil","tag-chronische-lymphatische-leukaemie","tag-cladribin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1112","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1112"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1112\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1112"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1112"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1112"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}